middle.news
Racura’s RC220 trials pass early safety checks as Korea expansion gathers pace
9:52am on Thursday 22nd of October, 2026 AEDT
•
Biotechnology and pharmaceuticals
Read Story
Racura’s RC220 trials pass early safety checks as Korea expansion gathers pace
9:52am on Thursday 22nd of October, 2026 AEDT
Key Points
HARNESS-1 cleared its first two-patient 50 mg/m² cohort
CPACS expanded to South Korea after its opening dose cohort
$30.735 million cash balance at 30 September
Management estimates funding through mid-2028
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE